Over the past year, the consensus price target for Tilray has more than doubled, rising from $4.50 to $10.00, reflecting growing optimism among equity analysts. While the majority of analysts now project a higher valuation, CIBC’s John Zamparo remains more cautious, setting a target of $8.00 ahead of the company’s second‐quarter earnings release on January 8, 2025. This divergence underscores a balance between bullish sentiment driven by recent strategic wins and lingering concerns about sustained profitability in an evolving regulatory environment.

Tilray’s partnerships in the beverage alcohol and wellness sectors have played a key role in its recent stock performance, which has nearly tripled over the last six months. Collaborations with global breweries and wellness brands have broadened Tilray’s distribution channels, contributing to strong sales growth in its beverage alcohol segment. In parallel, the launch of new wellness products—ranging from GMP-certified botanical oils to innovative topicals—has expanded its retail footprint across North America and Europe, positioning the company to capture share as consumer demand for premium cannabis offerings intensifies.

Analysts expect Tilray to report a 20-cent loss per share on quarterly revenue of approximately $210.95 million when it announces second‐quarter results on January 8, 2026. This projected decline in profitability contrasts with a narrow year-over-year revenue drop of around 0.6% but represents a marked improvement from the prior year’s one‐dollar‐per‐share loss. Tilray’s balance sheet remains robust, with a debt‐to‐equity ratio of 0.15 and a current ratio of 2.62, indicating ample liquidity to support continued investment in production capacity and product development.

A recent presidential executive order to expedite marijuana’s rescheduling to Schedule III status could eliminate the drag of Section 280E tax treatment, potentially unlocking millions of dollars in additional annual cash flow for Tilray. In response, the company launched its Tilray Medical USA subsidiary in December, aiming to capitalize on anticipated tax relief and expanded federal research allowances. Investors will be watching closely for management guidance on reinvestment of any tax savings into U.S. cultivation infrastructure and marketing initiatives that could accelerate revenue growth once federal regulations are revised.